Literature DB >> 12885448

A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma.

Claire Phillips1, Michael Guiney, Jennifer Smith, Peter Hughes, Kailash Narayan, George Quong.   

Abstract

A randomized prospective clinical trial was conducted to compare conventional high dose radiotherapy with hypofractionated, short course radiotherapy in poor prognosis patients with high grade glioma. The primary endpoint was overall survival.

Entities:  

Mesh：

Year:  2003        PMID： 12885448     DOI： 10.1016/s0167-8140(03)00206-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  18 in total

1.  [Malignant gliomas--radiotherapy].

Authors:  Annemarie Schratter-Sehn
Journal:  Wien Med Wochenschr       Date:  2006-06

Review 2.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

3.  Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults.

Authors:  John Buatti; Timothy C Ryken; Mark C Smith; Penny Sneed; John H Suh; Minesh Mehta; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

Review 4.  Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.

Authors:  Jeffrey Q Cao; Barbara J Fisher; Glenn S Bauman; Joseph F Megyesi; Christopher J Watling; David R Macdonald
Journal:  J Neurooncol       Date:  2011-11-22       Impact factor: 4.130

5.  Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.

Authors:  Mario Ammirati; Silky Chotai; Herbert Newton; Tariq Lamki; Lai Wei; John Grecula
Journal:  J Clin Neurosci       Date:  2013-10-03       Impact factor: 1.961

6.  Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).

Authors:  Silvia Scoccianti; Marco Krengli; Livia Marrazzo; Stefano Maria Magrini; Beatrice Detti; Vincenzo Fusco; Luigi Pirtoli; Daniela Doino; Alba Fiorentino; Laura Masini; Daniela Greto; Michela Buglione; Giovanni Rubino; Federico Lonardi; Fernanda Migliaccio; Salvino Marzano; Riccardo Santoni; Umberto Ricardi; Lorenzo Livi
Journal:  Radiol Med       Date:  2017-09-06       Impact factor: 3.469

7.  Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma.

Authors:  Christopher A Barker; Maria Chang; Joanne F Chou; Zhigang Zhang; Kathryn Beal; Philip H Gutin; Fabio M Iwamoto
Journal:  J Neurooncol       Date:  2012-06-12       Impact factor: 4.130

8.  Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.

Authors:  Matthias Guckenberger; Mario Mayer; Mathias Buttmann; Giles H Vince; Reinhart A Sweeney; Michael Flentje
Journal:  Strahlenther Onkol       Date:  2011-08-18       Impact factor: 3.621

9.  Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.

Authors:  Sara Pedretti; Laura Masini; Enrico Turco; Luca Triggiani; Marco Krengli; Bruno Meduri; Luigi Pirtoli; Paolo Borghetti; Ludovica Pegurri; Nada Riva; Roberto Gatta; Vincenzo Fusco; Silvia Scoccianti; Alessio Bruni; Umberto Ricardi; Riccardo Santoni; Stefano M Magrini; Michela Buglione
Journal:  J Neurooncol       Date:  2019-05-04       Impact factor: 4.130

Review 10.  Health-related quality of life in patients with high-grade glioma.

Authors:  Jin-xiang Cheng; Xiang Zhang; Bo-Lin Liu
Journal:  Neuro Oncol       Date:  2008-07-15       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.